Health TrialsbyHealthPanel

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

ConditionsCerebral HemorrhageAcute Lobar Haematoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Nīmes

About this trial

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.

Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.

An equivalent marker has also been described in gadolinium-enhanced MRI.

By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;

Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.

Disqualifiers

Patient refusing to participate

Trial population

Patients with acute cerebral hematoma from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy; who underwent a follow-up cerebral CT scan in the event of worsening or for follow-up.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • None, pure observational study

    Other intervention

    None, pure observational study

Treatment groups

128 Participants
are divided into 1 treatment group
Group A: patients with acute lobar and deep haematoma1 intervention

Trial outcomes

Primary outcomes

1

Presence of spot sign on gadolinium MRI

Presence of spot sign on gadolinium MRI (Yes/No)

Time frame
baseline
2

Morphologic description of gadolinium MRI spot sign

morphological (shape, location within the hematoma) description of spot signs on brain MRI

Time frame
baseline
3

Quantitative description of gadolinium MRI spot sign

Quantitative (number and categorial) description of spot signs on brain MRI

Time frame
baseline

Secondary outcomes

1

association of spot sign with hematoma expansion on follow-up CT

association of spot sign with hematoma expansion on follow-up CT(Yes/No)

Time frame
Baseline
2

Association with the underlaying pathology

Association with the underlaying pathology as identified by the authors (Yes/No)

Time frame
Baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Hospitalier Universitaire de Nīmes

Lead sponsor

Source ClinicalTrials.gov
Apply now